Identification of an <i>LDLR</i> variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells

Wen-Zhuo CHENG; Wei-Hua WANG; Ai-Ping DENG; Xiao DANG; Chao LIU; Xian-Can WANG; Ju-Yi LI; Si JIN

doi:10.26599/1671-5411.2023.05.003

Volume 20 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2023 > 20(5): 341-349

Please cite this article as: CHENG WZ, WANG WH, DENG AP, DANG X, LIU C, WANG XC, LI JY, JIN S. Identification of an LDLR variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells. J Geriatr Cardiol 2023; 20(5): 341−349. DOI: 10.26599/1671-5411.2023.05.003

Citation:

Please cite this article as: CHENG WZ, WANG WH, DENG AP, DANG X, LIU C, WANG XC, LI JY, JIN S. Identification of an LDLR variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells. J Geriatr Cardiol 2023; 20(5): 341−349. DOI: 10.26599/1671-5411.2023.05.003

Citation:

PDF( 11391 KB)

Identification of an LDLR variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells

doi: 10.26599/1671-5411.2023.05.003

Wen-Zhuo CHENG^{1, *},
Wei-Hua WANG^{2, *},
Ai-Ping DENG³,
Xiao DANG⁴,
Chao LIU⁵,
Xian-Can WANG^{6
,
,},
Ju-Yi LI^{3
,
,},
Si JIN^{1
,
,}

1.
Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2.
Department of Party Affairs, Pulmonary and Critical Care Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3.
Department of Pharmacy, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4.
Department of Prenatal Diagnostic Center, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangdong, China
5.
Hubei Key Laboratory of Diabetes and Angiopathy, Hubei University of Science and Technology, Wuhan, Hubei, China
6.
Department of Cardiovascular Surgery, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

^*The authors contributed equally to this manuscript

More Information

Corresponding author: dr_can@126.com (WANG XC); ljywxf110@163.com (LI JY); jinsi@hust.edu.cn (JIN S)
Available Online: 2023-06-01
Publish Date: 2023-05-28

Abstract

Abstract

BACKGROUND Familial hypercholesterolemia (FH) is a common autosomal dominant hereditary disease. Its early diagnosis and intervention significantly improve the patient’s quality of life. However, there are few types of research on the FH pathogenic genes in China. METHODS In this study, we recruited a family diagnosed with FH and used whole exome sequencing (WES) to analyze the proband variants. Intracellular cholesterol level, reactive oxygen species (ROS) level, and the expression of pyroptosis-related genes were detected after overexpression of wild-type or variant LDLR in L02 cells. RESULTS A heterozygous missense variant predicted to be deleterious to LDLR (c.1879G > A, p.Ala627Thr) was identified in the proband. Mechanistically, intracellular cholesterol level, ROS level, and the expression of pyroptosis-related genes, nucleotide-binding oligomerization domain-like receptor family protein 3 (NLRP3) inflammasome and components (caspase 1, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and NLRP3), gasdermin D (GSDMD), interleukin (IL) -18, IL-1β was elevated in the variant LDLR group, which was attenuated by inhibition of ROS. CONCLUSIONS FH is associated with a variant (c.1879G>A, p.Ala627Thr) in the LDLR gene. Regarding the mechanism, the ROS/NLRP3-mediated pyroptosis in hepatic cells may contribute to the pathogenesis of the LDLR variant.

FullText(HTML)

References(32)

References

[1]	Amersfoort J, Schaftenaar FH, Douna H, et al. Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells. Cardiovasc Res 2021; 117: 1309−1324. doi: 10.1093/cvr/cvaa208
[2]	Foody JM, Vishwanath R. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity. J Clin Lipidol 2016; 10: 970−986. doi: 10.1016/j.jacl.2016.04.009
[3]	Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Gene 2003; 34: 154−156. doi: 10.1038/ng1161
[4]	Alnouri F, Athar M, Al-Allaf FA, et al. Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia. Atherosclerosis 2018; 277: 425−433. doi: 10.1016/j.atherosclerosis.2018.06.878
[5]	Pirillo A, Garlaschelli K, Arca M, et al. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler Suppl 2017; 29: 17−24. doi: 10.1016/j.atherosclerosissup.2017.07.002
[6]	Danyel M, Ott CE, Grenkowitz T, et al. Evaluation of the role of STAP1 in Familial Hypercholesterolemia. Sci Rep 2019; 9: 11995. doi: 10.1038/s41598-019-48402-y
[7]	Cao YX, Wu NQ, Sun D, et al. Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. J Transl Med 2018; 16: 345. doi: 10.1186/s12967-018-1737-7
[8]	de Paiva Silvino JP, Jannes CE, Tada MT, et al. Cascade screening and genetic diagnosis of familial hypercholesterolemia in clusters of the Southeastern region from Brazil. Mol Biol Rep 2020; 47: 9279−9288. doi: 10.1007/s11033-020-06014-0
[9]	Bandyopadhyay D, Ashish K, Hajra A, et al. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. J Lipids 2018; 2018: 3179201.
[10]	Flannick J, Mercader JM, Fuchsberger C, et al. Exome sequencing of 20, 791 cases of type 2 diabetes and 24, 440 controls. Nature 2019; 570: 71−76. doi: 10.1038/s41586-019-1231-2
[11]	Jelin AC, Vora N. Whole Exome Sequencing: Applications in Prenatal Genetics. Obstet Gynecol Clin North Am 2018; 45: 69−81. doi: 10.1016/j.ogc.2017.10.003
[12]	Hansen MC, Haferlach T, Nyvold CG. A decade with whole exome sequencing in haematology. Br J Haematol 2020; 188: 367−382. doi: 10.1111/bjh.16249
[13]	Xiang R, Fan LL, Lin MJ, et al. The genetic spectrum of familial hypercholesterolemia in the central south region of China. Atherosclerosis 2017; 258: 84−88. doi: 10.1016/j.atherosclerosis.2017.02.007
[14]	van den Boomen DJH, Sienkiewicz A, Berlin I, et al. A trimeric Rab7 GEF controls NPC1-dependent lysosomal cholesterol export. Nat Commun 2020; 11: 5559−5559. doi: 10.1038/s41467-020-19032-0
[15]	Ochiai A, Miyata S, Shimizu M, et al. Piperine induces hepatic low-density lipoprotein receptor expression through proteolytic activation of sterol regulatory element-binding proteins. PloS one 2015; 10: e0139799. doi: 10.1371/journal.pone.0139799
[16]	Bjune K, Wierød L, Naderi S. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms. PloS one 2019; 14: e0218537−e0218537. doi: 10.1371/journal.pone.0218537
[17]	Ho CM, Ho SL, Jeng YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. J Inflamm (Lond) 2019; 16: 7. doi: 10.1186/s12950-019-0211-5
[18]	Burillo-Sanz S, Montes-Cano MA, García-Lozano JR, et al. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. Sci Rep 2017; 7: 8453−8453. doi: 10.1038/s41598-017-09164-7
[19]	Qiu T, Pei P, Yao X, et al. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis 2018; 9: 946−946. doi: 10.1038/s41419-018-1004-0
[20]	Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ (Clinical research ed) 1991; 303: 893−896. doi: 10.1136/bmj.303.6807.893
[21]	Iacovazzo D, Flanagan SE, Walker E, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A 2018; 115: 1027−1032. doi: 10.1073/pnas.1712262115
[22]	Pace NP, Craus J, Felice A, Vassallo J. Case Report: Identification of an HNF1B p. Arg527Gln mutation in a Maltese patient with atypical early onset diabetes and diabetic nephropathy. BMC Endocr Disord 2018; 18: 28.
[23]	Sunyaev S, Ramensky V, Bork P. Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet 2000; 16: 198−200. doi: 10.1016/S0168-9525(00)01988-0
[24]	Grebe A, Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep 2013; 15: 313. doi: 10.1007/s11926-012-0313-z
[25]	Sun LY, Zhang YB, Jiang L, et al. Identification of the gene defect responsible for severe hypercholesterolaemia using whole-exome sequencing. Sci Rep 2015; 5: 11380. doi: 10.1038/srep11380
[26]	Brunham LR, Ruel I, Aljenedil S, et al. Canadian cardiovascular society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol 2018; 34: 1553−1563. doi: 10.1016/j.cjca.2018.09.005
[27]	Cayo MA, Mallanna SK, Di Furio F, et al. A drug screen using human ipsc-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia. Cell Stem Cell 2017; 20: 478−489.e475. doi: 10.1016/j.stem.2017.01.011
[28]	van de Sluis B, Wijers M, Herz J. News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1. Curr Opin Lipidol 2017; 28: 241−247. doi: 10.1097/MOL.0000000000000411
[29]	Cheng X, Ding J, Zheng F, et al. Two mutations in LDLR gene were found in two Chinese families with familial hypercholesterolemia. Mol Biol Rep 2009; 36: 2053−2057. doi: 10.1007/s11033-008-9416-z
[30]	Oommen D, Kizhakkedath P, Jawabri AA, et al. Proteostasis regulation in the endoplasmic reticulum: an emerging theme in the molecular pathology and therapeutic management of familial hypercholesterolemia. Front Genet 2020; 11: 570355. doi: 10.3389/fgene.2020.570355
[31]	Sun XM, Patel DD, Webb JC, et al. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-negative phenotype. Arterioscler Thromb 1994; 14: 85−94.
[32]	Jiang L, Sun LY, Dai YF, et al. The distribution and characteristics of LDL receptor mutations in China: A systematic review. Sci Rep 2015; 5: 17272. doi: 10.1038/srep17272